Driver mutation status of the study groups of patients
| Mutation status | LC control | LC-COPD |
| Subjects n | 20 | 30 |
| KRAS, n (%) | ||
| No mutation | 10 (76.9) | 12 (75.0) |
| Mutation | 3 (23.1) | 4 (25.0) |
| EGFR, n (%) | ||
| No mutation | 11 (84.6) | 14 (87.5) |
| Mutation | 2 (15.4) | 2 (12.5) |
| ALK, n (%) | ||
| No mutation | 13 (100.0) | 16 (100.0) |
| Mutation | 0 (0) | 0 (0) |
Categorical variables are expressed as the number of patients per group and the respective percentage in each group with respect to the total population. LC: lung cancer; KRAS: Kirsten rat sarcoma virus; EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase. Statistical significance: no statistically significant differences were found between LC-COPD and LC patients.